<DOC>
	<DOCNO>NCT01546116</DOCNO>
	<brief_summary>- Entecavir one option treatment lamivudine resistant chronic hepatitis B ( CHB ) . - In case entecavir resistance , adefovir could use . However , sequential monotherapy may result multidrug resistance . - It think adefovir lamivudine combination therapy reduce risk adefovir resistance , thereby continue therapy lead suppression hepatitis B virus ( HBV ) DNA undetectable patient entecavir resistance . - This study aim evaluate efficacy adefovir lamivudine combination therapy CHB patient entecavir resistance .</brief_summary>
	<brief_title>Adefovir Lamivudine Entecavir Resistance ( ALTER Study )</brief_title>
	<detailed_description>Entecavir potent antiviral agent treatment chronic hepatitis B ( CHB ) . However , incidence entecavir resistance increase 50 % 5th year lamivudine-refractory CHB patient . Considering cross resistance profile , adefovir good option manage entecavir resistance . However adefovir monotherapy may lead adefovir resistance , entecavir resistant hepatitis B virus ( HBV ) retain lamivudine resistance . Previously , combination adefovir lamivudine report effective patient entecavir resistance , case report form . No data available combination therapy sufficient number patient . It think adefovir lamivudine combination therapy reduce risk adefovir resistance , thereby continue combination treatment result suppression HBV DNA undetectable patient entecavir resistance . The aim study evaluate efficacy adefovir lamivudine combination therapy CHB patient entecavir resistance .</detailed_description>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . Chronic hepatitis B patient ( positive HBsAg &gt; 6 month ) 2 . Age &gt; 18 year old 3 . History treatment entecavir 6 month 4 . Proven entecavir resistant mutation ( rtT184S/A/I/L/G/C/M , rtS202G/C/I , rtM250I/V ) 5 . HBV DNA level &gt; 2000 IU/mL 6 . Compensated liver disease ( ChildPughTurcotte score 7 ; prothrombin time prolong 3 sec ULN INR 1.5 ; serum albumin &gt; 3 g/dL ; total bilirubin &lt; 2.5 mg/dL ; No history variceal bleeding , ascites , hepatic encephalopathy ) 7 . Patients willing give inform consent 1 . Out inclusion criterion 2 . Any one follow Serum phosphorus level 2.4 mg/dL Serum creatinine level 1.5 mg/dL creatinine clearance &lt; 50 mL/min Absolute neutrophil count lower 1000 cell/mL Hb level 10 g/dL ( male ) , 9 g/dL ( female ) Serum AFP &gt; 100 ng/mL 3 . History treatment interferonalfa , thymosinalfa 1 , nucleos ( ) ide analogue entecavir 6 month screen 4 . History adefovir resistance ( detection rtA181T/Vor rtN236T screen past ) 5 . Recipient organ transplantation 6 . Positive antibody test HIV , HCV HDV 7 . Pregnant breast feed woman 8 . Patients hepatocellular carcinoma uncontrolled malignant disease 9 . Habitual alcohol drinker ( &gt; 140 g/week men , &gt; 70 g/week woman )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>adefovir</keyword>
	<keyword>lamivudine</keyword>
	<keyword>entecavir resistance</keyword>
</DOC>